LENOX, Mass.--(BUSINESS WIRE)--New York-based real estate investor 388 Ventures has closed on the acquisition of a portfolio of historic bed-and-breakfasts in Lenox, MA. The portfolio was assembled ...
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, ...
Roche’s CT-388 Phase 2 showed competitive 48-week weight loss. I believe this supports a credible late-entry push into the massive obesity/GLP market. Roche’s Genentech plans to start its Phase 3 this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results